Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zealand Pharma A/S (NASDAQ: ZEAL).

Full DD Report for ZEAL

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZEAL)

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Company announcement - No. 22 / 2018 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 14, 2018 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and d...
Source: GlobeNewswire
Date: September, 14 2018 03:46
Premarket analyst action - healthcare
Zealand Pharma A/S (NASDAQ: ZEAL ) resumed with Overweight rating at Morgan Stanley following its $205M deal with Royalty Pharma. More news on: Zealand Pharma, Intercept Pharmaceuticals, Vital Therapies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 12 2018 08:34
Midday Gainers / Losers (09/07/2018)
Gainers:  OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:47
Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences
Press release - No. 19 / 2018 Zealand Pharma to attend J.P. Morgan Cazenove and Morgan Stanley Global Healthcare Conferences Copenhagen, September 7, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the J.P. Morgan Caz...
Source: GlobeNewswire
Date: September, 07 2018 08:18
Zealand Pharma shares halted pending news
Nasdaq has suspended trading in Zealand Pharma (NASDAQ: ZEAL ) pending the release of news. More news on: Zealand Pharma, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 06 2018 16:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1417.9617.9118.1017.7810,276

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143535100.0000Short
2018-12-13142296.1135Cover
2018-12-122,0052,05497.6144Short
2018-12-101,1541,27990.2267Short
2018-12-061005,4571.8325Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZEAL.


About Zealand Pharma A/S (NASDAQ: ZEAL)

Logo for Zealand Pharma A/S (NASDAQ: ZEAL)

Zealand Pharma A/S was founded in and is a biotechnology company focused on the discovery, design and development of innovative peptide based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim.

 

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: ZEAL)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 07 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: August, 17 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 31 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: July, 13 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 11 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 31 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 29 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 22 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 16 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 27 2018

     

     


    Daily Technical Chart for (NASDAQ: ZEAL)

    Daily Technical Chart for (NASDAQ: ZEAL)


    Stay tuned for daily updates and more on (NASDAQ: ZEAL)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ZEAL)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZEAL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZEAL and does not buy, sell, or trade any shares of ZEAL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/